Can hyperlipidemia cause eyelid hordeola (styes)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can High Cholesterol Cause Eye Hordeolums (Styes)?

No, high cholesterol does not directly cause hordeolums (styes), but there is emerging evidence suggesting a possible association between metabolic syndrome components—including elevated cholesterol—and eyelid inflammation conditions like blepharitis, which is a known risk factor for recurrent hordeolums.

The Evidence Linking Cholesterol to Eyelid Disease

The relationship between cholesterol and eyelid conditions is indirect and relates primarily to blepharitis rather than hordeolums specifically:

  • Metabolic syndrome components, including elevated total cholesterol, LDL cholesterol, and triglycerides, have been associated with higher rates of blepharitis in observational studies 1.

  • Patients with increased waist circumference, systolic blood pressure, higher glucose, higher total cholesterol and LDL cholesterol, and higher triglycerides were more likely to have a diagnosis of blepharitis 1.

  • Interestingly, statin use was associated with a lower risk of blepharitis in population-based studies, suggesting that cholesterol-lowering may have protective effects on eyelid inflammation 1.

  • However, the guidelines explicitly state that "further research is needed to examine the relationship between cholesterol and blepharitis," indicating this association is not yet definitively established 1.

The Actual Causes of Hordeolums

Hordeolums have well-established causes unrelated to cholesterol:

  • Hordeolums are typically caused by bacterial infection (usually Staphylococcus aureus) of the eyelid glands, presenting as painful, erythematous nodules at the eyelid margin with rapid onset and acute inflammation 2, 3.

  • The primary risk factors for hordeolums are bacterial blepharitis, meibomian gland dysfunction, poor eyelid hygiene, and underlying skin conditions like rosacea or seborrheic dermatitis 2, 3, 4.

  • Children with a history of styes have an increased risk of developing adult rosacea, but this represents a different causal pathway unrelated to cholesterol 1.

Clinical Implications

When evaluating patients with recurrent hordeolums:

  • Focus on identifying and treating underlying blepharitis, meibomian gland dysfunction, rosacea, and seborrheic dermatitis as these are the established predisposing conditions 2, 3.

  • Implement regular eyelid hygiene measures, warm compresses, and treatment of underlying skin conditions as prevention strategies 2, 3.

  • While screening for metabolic syndrome components may be reasonable in patients with chronic blepharitis, there is insufficient evidence to attribute hordeolums directly to hyperlipidemia 1.

Important Distinction: Xanthelasma vs. Hordeolum

Do not confuse hordeolums with xanthelasmas:

  • Xanthelasmas are superficial fat deposits around the eyelids that ARE associated with hyperlipidemia and familial hypercholesterolemia, and these can regress with aggressive lipid-lowering therapy 5.

  • Hordeolums are acute infectious/inflammatory lesions that are NOT caused by lipid deposits 2, 3, 4.

Bottom Line for Clinical Practice

Treat recurrent hordeolums by addressing their actual causes—bacterial blepharitis, meibomian gland dysfunction, and poor eyelid hygiene—rather than focusing on cholesterol levels 2, 3, 4. While the metabolic syndrome-blepharitis association is intriguing, it remains investigational and should not change current management of hordeolums 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Chalazion and Hordeolum Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Assessment and Management of Bilateral Hordeolum

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of Internal Hordeolum

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Rapid resolution of xanthelasmas after treatment with alirocumab.

Journal of clinical lipidology, 2016

Related Questions

What are the symptoms and treatment options for hyperlipidemia?
What are the different risk groups for hyperlipidemia management according to the American Heart Association (AHA), American College of Cardiology (ACC), and American Association of Clinical Endocrinologists (AACE) guidelines?
What is the best treatment plan for a 22-year-old with hyperlipidemia, who is moderately active, follows a Standard American Diet, and consumes alcohol?
What is the treatment for hyperlipidemia?
What is the impact of correcting hyperlipidemia on cardiovascular risk?
What is the emergency treatment protocol for adrenal crisis in a patient with known or unrecognised adrenal insufficiency?
What is the appropriate ambroxol dose for a child based on weight and age?
Is a Bartholin gland cyst or abscess considered a perineal abscess?
What are the possible ocular and systemic causes of blurred vision?
What are the recommended dosing, monitoring, contraindications, side effects, and alternative therapies for bimatoprost 0.01% ophthalmic solution in a patient with open‑angle glaucoma or ocular hypertension?
A 27‑year‑old woman, 2 weeks postpartum after cesarean delivery for severe pre‑eclampsia at 30 weeks gestation (infant 1 kg), now has persistent severe hypertension (150‑170 mmHg systolic), elevated serum creatinine (284 µmol/L), modestly elevated blood urea nitrogen (10.97 mg/dL), elevated alanine aminotransferase (137 U/L), aspartate aminotransferase (66 U/L), lactate dehydrogenase (579 U/L), metabolic acidosis (pH 7.27, bicarbonate 14.4 mmol/L, PCO₂ 26 mmHg), hyponatremia (Na 130 mmol/L), borderline hypokalemia (K 3.6 mmol/L), hypomagnesemia (Mg 0.76 mg/dL), and is taking losartan 50 mg. What is the complete differential diagnosis, which investigations are still missing, and what is the comprehensive management plan according to Harrison and Philippine obstetric‑nephrology guidelines, presented as a SOAP‑formatted chart with orders?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.